/PTHS
PTHS Stock - Pelthos Therapeutics Inc.
Healthcare|BiotechnologyNYSE
$25.63+13.06%
+$2.96 (+13.06%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+117.2%upside
Target: $55.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PTHS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$25.37 – $25.89
TARGET (TP)$55.67
STOP LOSS$23.58
RISK/REWARD1:14.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta4.12
52W High$54.29
52W Low$5.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $199,934 |
| Gross Profit | N/A | N/A | N/A | N/A | $199,934 |
| Gross Margin | N/A | N/A | N/A | N/A | 100.0% |
| Operating Income | $-7,571,449 | $-6,862,284 | $-2,318,159 | $-838,996 | $-1,353,867 |
| Net Income | $-7,955,338 | $-7,380,793 | $-2,458,589 | $-595,387 | $-660,584 |
| Net Margin | N/A | N/A | N/A | N/A | -330.4% |
| EPS | $-13.54 | $-12.80 | $-4.26 | $-1.00 | $-1.15 |
Company Overview
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$54
Average Target
↑ 111.7% Upside
Now
$50
Low
$54
Average
$60
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Lake Street | Initiation | Buy | $50 |
| December 3rd 2025 | H.C. Wainwright | Initiation | Buy | $60 |
| November 25th 2025 | Roth Capital | Initiation | Buy | $57 |
| September 2nd 2025 | Oppenheimer | Initiation | Outperform | $50 |
Earnings History & Surprises
PTHSBeat Rate
0%
Last 2 quarters
Avg Surprise
-382.3%
EPS vs Estimate
Beats / Misses
0/2
Last 12 quarters
Latest EPS
$-5.30
Q4 2025
EPS Surprise History
Q3 25
-73.5%
$-5.38vs$-3.10
Q4 25
-691.0%
$-5.30vs$-0.67
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-2.88 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.67 | $-5.30 | -691.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-3.10 | $-5.38 | -73.5% | ✗ MISS |
Latest News
Pelthos Signs First Big Deal to Expand Access to Its At-Home Treatment for Molluscum
📈 PositiveBenzinga•Dec 4, 2025, 12:03 PM
Lake Street Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $50
📈 PositiveBenzinga•Dec 3, 2025, 07:03 PM
HC Wainwright & Co. Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $60
📈 PositiveBenzinga•Dec 3, 2025, 12:06 PM
Roth Capital Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $57
📈 PositiveBenzinga•Nov 25, 2025, 06:18 PM•Also:
Oppenheimer Reiterates Outperform on Pelthos Therapeutics, Raises Price Target to $57
📈 PositiveBenzinga•Nov 14, 2025, 05:28 PM
Pelthos Therapeutics Q3 EPS $(5.30) Misses $(0.55) Estimate, Sales $7.406M Beat $4.380M Estimate
➖ NeutralBenzinga•Nov 13, 2025, 11:46 AM
Pelthos Therapeutics shares are trading lower. The company announced it acquired the the U.S. commercialization rights to Xepi Cream, 1%, from Biofrontera and Ferrer Internacional and closed on an $18 million private convertible notes financing with existing investors.
➖ NeutralBenzinga•Nov 7, 2025, 04:10 PM•Also:
Biofrontera Announces The Sale Of Its U.S. License For Xepi Cream To Pelthos Therapeutics. The Company Received $3M Upfront, Will Get $1M Upon Product Availability, And May Earn Up To $6M In Milestone Payments Tied To Future U.S. Sales Performance.
📈 PositiveBenzinga•Nov 7, 2025, 01:03 PM•Also:
EXCLUSIVE: Pelthos Therapeutics Tells Benzinga 'Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™'
📈 PositiveBenzinga•Nov 7, 2025, 12:50 PM
EXCLUSIVE: Pelthos Therapeutics Tells Benzinga 'Private convertible notes financing will support the acquisition and re-launch of Xepi, accelerate the commercialization of ZELSUVMI for molluscum contagiosum, and for general working capital purposes'
📈 PositiveBenzinga•Nov 7, 2025, 12:50 PM
EXCLUSIVE: Pelthos Therapeutics Tells Benzinga Co. Announces $18M private Convertible Notes Financing
📈 PositiveBenzinga•Nov 7, 2025, 12:50 PM
EXCLUSIVE: Pelthos Therapeutics Tells Benzinga Co. Announced It Has Acquired The U.S Commercialization Rights To Xepi (ozenoxacin) Cream, 1% From Biofrontera Inc. And Ferrer Internacional S.A.
📈 PositiveBenzinga•Nov 7, 2025, 12:50 PM•Also:
Oppenheimer Initiates Coverage On Pelthos Therapeutics with Outperform Rating, Announces Price Target of $50
📈 PositiveBenzinga•Sep 2, 2025, 12:20 PM
Frequently Asked Questions about PTHS
What is PTHS's current stock price?
Pelthos Therapeutics Inc. (PTHS) is currently trading at $25.63 per share. The stock has moved +13.06% today.
What is the analyst price target for PTHS?
The average analyst price target for PTHS is $55.67, based on 1 analyst.
What sector is Pelthos Therapeutics Inc. in?
Pelthos Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is PTHS's market cap?
Pelthos Therapeutics Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does PTHS pay dividends?
No, Pelthos Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCASI
CASI Pharmaceuticals, Inc.
$0.81
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CLSD
Clearside Biomedical, Inc.
$1.00
Mkt Cap: $0.0B
ENLV
Enlivex Therapeutics Ltd.
$0.83
Mkt Cap: $0.0B
KAPA
Kairos Pharma, Ltd.
$0.86
Mkt Cap: $0.0B
LEXX
Lexaria Bioscience Corp.
$0.58
Mkt Cap: $0.0B
LIXT
Lixte Biotechnology Holdings, Inc.
$4.32
Mkt Cap: $0.0B
LSTA
Lisata Therapeutics, Inc.
$2.06
Mkt Cap: $0.0B
MTVA
MetaVia Inc.
$8.62
Mkt Cap: $0.0B
PASG
Passage Bio, Inc.
$9.59
Mkt Cap: $0.0B
Explore stocks similar to PTHS for comparison